The effects of single and combined selective blockade of the sympathetic alpha-and beta-receptors were examined in patients with severe hypertension (diastolic pressure > I20 mmHg) uncomplicated by cardiac or renal failure. Given intravenously to 12 patients the alpha-receptor antagonist phentolamine and the beta-receptor antagonist oxprenolol together produced a reduction in systemic arterial pressure to normal levels and a reduction in left ventricular end-diastolic pressure without change in the cardiac output; these effects were maintained. Separately, neither drug resulted in such a satisfactory circulatory reponse. In 6 patients continued oral treatment for 6 months with progressively increased doses of oxprenolol alone up to 480 mg daily, in divided doses, produced a moderate reduction in blood pressure. The addition of oral phentolamine 20 mg t.d.s. resulted in an immediate reduction of blood pressure to normal levels, both at rest and during walking, without postural or other side effects, and without habituation to treatment over a period of 6 months.
The effects of single and combined selective blockade of the sympathetic alpha-and beta-receptors were examined in patients with severe hypertension (diastolic pressure > I20 mmHg) uncomplicated by cardiac or renal failure. Given intravenously to 12 patients the alpha-receptor antagonist phentolamine and the beta-receptor antagonist oxprenolol together produced a reduction in systemic arterial pressure to normal levels and a reduction in left ventricular end-diastolic pressure without change in the cardiac output; these effects were maintained. Separately, neither drug resulted in such a satisfactory circulatory reponse. In 6 patients continued oral treatment for 6 months with progressively increased doses of oxprenolol alone up to 480 mg daily, in divided doses, produced a moderate reduction in blood pressure. The addition of oral phentolamine 20 mg t.d.s. resulted in an immediate reduction of blood pressure to normal levels, both at rest and during walking, without postural or other side effects, and without habituation to treatment over a period of 6 months. Arguments are presented that such treatment may have significant advantages over other current medicinal treatments of severe hypertensive vascular disease.
In uncomplicated essential hypertension the raised blood pressure is accompanied by a normal cardiac output (Taylor, Donald, and Bishop, I957) . The increased peripheral resistance is uniformly distributed throughout all the regional circulations and resides predominantly in the peripheral arterioles (Freis, I960) . These vessels regulate the resistance in many of the regional vascular beds, and particularly in the kidney, through sympathetic alphaadrenergic receptors (Moran, I966) .
Thus it is reasonable to expect that drugs which possess both vasodilator properties and also the ability to inhibit stimulation of the adrenergic alpha-receptors may offer substantial advantages over other less specific agents in the treatment of hypertensive vascular disease. Phentolanine, an alpha-receptor antagonist with conspicuous vasodilator properties (Taylor et al., i965a, b; Majid, Sharma, and Taylor, 197i) , has been shown to be effective in acutely lowering the blood pressure of hypertensive patients (Taylor et al., i965a) . However, in subjects with intact cardiovascular reflexes the hypotensive effects of the drug are offset by an accompanying increase in cardiac output (Taylor Received I965a; Majid et al., 197I) . For this reason it is logical to combine drugs that block both the alphaand beta-adrenoreceptors so that the reflex increase in sympathetic stimulation of the heart that occurs in response to the fall in blood pressure induced by alpha-receptor blockade is prevented by inhibition of the cardiac beta-receptors.
The following investigation was, therefore, undertaken to test this thesis by acute haemodynamic studies in patients with severe hypertensive disease and to determine the clinical effectiveness of the combination of oral alpha-and beta-receptor antagonists in the longer term treatment of these patients.
Patients and methods The scientific reasons for the study, the proposed programme of investigation, its relation to their individual treatment, and its possible wider therapeutic implications were explained to each patient; the voluntary nature of the co-operation requested was emphasized. All patients freely consented to the study without inducement (Medical Research Council, I964; Ormrod, I968). In group A, the programme of investigation started with 6 minutes of supine leg exercise followed by 20 minutes of rest. Oxprenolol was then injected and IS minutes later the rest and exercise studies were repeated in reverse order. At the end of the second 6-minute period of exercise, phentolamine infusion was started and the rate adjusted to lower the mean systemic arterial pressure to 20 to 30 mmHg. Twenty minutes later the rest and exercise studies were repeated for the third time.
Design of investigation
In group B the order of drug administration was reversed; the infusion of phentolamine was temporarily discontinued during the second post-exercise recovery period in this group so that patients in both groups received approximately the same total amount of phentolamine (20-40 mg). The times and doses of phentolamine and oxprenolol used were decided after pilot studies in ourselves had confirmed the effectiveness of each drug in producing a conspicuous degree of alphaor beta-receptor blockade over the time scale of the intended investigation. Cardiac output was measured by the direct oxygen Fick method during the last four minutes of each rest period and during the final two minutes of each exercise period. Intravascular pressures and electrocardiogram were displayed and recorded continuously throughout.
B) Clinical studies An oral preparation of phentolamine was supplied at our special request by Ciba Laboratories, Horsham, after initial studies had confirmed the antihypertensive effectiveness of the intravenous preparation in combination with oxprenolol. Thus, only the last six patients were able to be treated on a direct follow-through basis from the intravenous studies, without the intervention of other antihypertensive treatment.
During their initial hospital admission 6 patients were walked daily on a motor-driven treadmill at 2 m.p.h. on a I00 incline for I0 minutes, a level of exercise that was well within the usual range of their normal everyday exertion. Sphygmomanometric blood pressure and electrocardiographically determined heart rate were measured in duplicate after lying supine for io (Taylor et al., 1974) . Phentolamine 20 mg t.d.s. (6o mg daily) was then added to this regimen and out-patient observations continued. This dose of phentolamine was used as preliminary observations conducted throughout the day showed that 20 mg produced its maximal antihypertensive effect within one hour with an effective duration of 3 to 6 hours (Fig. 5) . Similar hour-by-hour studies were carried out in each patient at monthly intervals after the addition of phentolamine to determine the magnitude and duration of its antihypertensive activity in these circumstances. At each out-patient clinic, bodyweight, serum, sodium, potassium, chloride, and urea, and electrocardiogram I Combined results (Fig. 3 , Table I ) The net result of oxprenolol and phentolamine together in all I2 patients was a reduction in systemic arterial pressure to normal levels both at rest and during exercise. This was achieved without any change in the normal resting cardiac output or in the output response to exercise. There was a significant reduction in the left ventricular end-diastolic pressure both at rest and during exertion.
Clinical studies (Fig. 4 The addition of phentolamine produced a further substantial reduction in systemic blood pressure to normal levels both at rest and during exercise without symptomatic postural effects. The magnitude and duration of the antihypertensive activity of oral phentolamine in these circumstances is illustrated in Fig. 5 . The reduction in systolic and diastolic pressures after the addition of phentolamine to oxprenolol was statistically significant lying (systolic: P < o ooi; diastolic: P <o oi), standing (systolic: P<o-oi; diastolic: P<o-ooi), and walking (systolic: P < o oi; diastolic: P <o os) compared to the values with oxprenolol alone. The effect on the blood pressure of the combination of oxprenolol and phentolamine persisted unchanged for more than 6 months, the minimum length of study in all subjects.
No side effects of the combined oral treatment were observed except in one patient who complained of slight nausea on first taking phentolamine; this symptom disappeared when the tablets were taken with food. Throughout the year of follow-up in each of these patients, no changes were Discussion The rationale for the use of vasodilator drugs in combination with beta-receptor antagonists in the treatment of essential hypertension was outlined in the introduction to this report. The results of the haemodynamic studies support the thesis that partial blockade of the cardiac beta-receptors augments the blood pressure lowering effects of the vasodilator and alpha-receptor antagonist phentolamine by reducing the sympathetic stimulation of the heart that occurs in response to the fall in blood pressure. The blockade of the cardiac beta-receptors can also be expected to counteract the cardiac stimulation that results from the release of endogenous catecholamines by phentolamine (Gould, Zahir, and Ettinger, I969) . Oxprenolol and phentolamine in combination produced a more conspicuous reduction in blood pressure than either drug alone. Furthermore, the increase in left ventricular enddiastolic pressure due to beta-blockade alone was nullified by the addition of phentolamine, and conversely the disadvantageous tachycardia and increase in cardiac output with phentolamine alone was completely counteracted by the addition of oxprenolol. In these haemodynamic terms, the The clinical follow-up studies with oral treatment of these patients with this combination of drugs were equally promising. Though oxprenolol alone produced a moderate reduction in the arterial pressure in the majority of the patients, in none was the blood pressure of these severely hypertensive patients reduced to clinically satisfactory levels. The addition of a relatively small dose of oral phentolamine to this regimen produced a further conspicuous reduction in blood pressure, in every patient to normal levels without postural hypotension and with a normal response (small increase) to exercise. This antihypertensive activity of oral phentolamine was observed for 3 to 6 hours after each oral dose and its effectiveness was maintained in all patients for longer than six months without habituation.
The combination of oxprenolol (480 mg daily) and phentolamine (6o mg daily) during this time was unaccompanied by any symptomatic side-effects or any untoward change in body weight, heart size, electrocardiogram, renal, or liver function.
However, the study can be criticized from a number of aspects. The rigid criteria employed for their selection almost certainly resulted in a cohort of patients infrequently seen in routine clinical practice. Though this must necessarily limit the wider clinical application of these results, clinical homogeneity of the patient group is essential if the results of such studies are to be therapeutically valid. It must also be pointed out that no attempt was made to equate the relative degree of either alpha-or betareceptor blockade achieved either in the haemodynamic or in the clinical studies in these patients. The doses of both drugs used in both situations were empirically chosen and no attempt was made to determine the dose-response relation for either drug singly or in combination. In fact, the complete response of all patients in this group of severely hypertensive patients suggests that smaller doses of these drugs, particularly that of the beta-receptor antagonist, may have achieved equally beneficial results; the effects of small doses should certainly be explored in any future trial of alpha-and betablockers in hypertension. Finally, it must be emphasized that though every effort was made to remove measurement bias, as by the use of a randomzero sphygmomanometer, the clinical studies were not double-blind in design. Though these provisos relegate the significance of these results to those of a promising preliminary report, we consider that the objective nature of the measurements furnish sufficient evidence to encourage further investigation of this treatment in severe hypertension.
Vasodilator drugs with alpha-receptor blocking activity in combination with beta-receptor antagonists have two distinct advantages over the use of beta-receptor inhibitors alone in the treatment of hypertension. The reduction in blood pressure produced by vasodilator drugs results in a lowering of impedance to ejection of blood from the ventricle, thus reducing left ventricular pressure work. The beta-receptor antagonists reduce blood pressure largely by reducing cardiac output, peripheral resistance remaining unchanged or even increasing (Majid et al., 1970) . The effects on the heart of these two methods of achieving blood pressure reduction were clearly contrasted in the present study. Phentolamine resulted in a reduction in blood pressure and a decrease in left ventricular enddiastolic pressure. Beta-receptor blockade alone resulted in a lesser reduction in blood pressure at the expense of an increase in left ventricular enddiastolic pressure. In combination the antihypertensive effects of the two drugs were summated and associated with a reduction in left ventricular enddiastolic pressure. The other major advantage of the drugs that block vasoconstrictive alpha-receptors in the treatment of hypertensive disease depends on their ability to inhibit the renal vascular effects of sympathetic stimuli. The alpha-receptors play a key role in the regulation of the circulation through the kidney (Handley and Moyer, I954 ). An increase in sympathetic activity whether due to emotion, excitement, exercise, trauma, or the incidental fall in blood pressure that occurs after beta-receptor antagonists alone, results in vasoconstriction of the renal vessels due to alpha-receptor activity. Blockade of these receptors by preventing or reducing such frequent shutdown of the renal vessels may retard or even prevent the progression of renal vascular disease, which is still one of the major causes of death in hypertension (Smirk and Hodge, I963) .
A number of studies involving selective blockade of the sympathetic alpha-and beta-receptors alone or in combination have been reported. Alone, the alpha-receptor antagonists never achieved popularity in the treatment of hypertension. Though phentolamine was specifically introduced for this purpose (Moyer and Caplovitz, I953) , doses up to goo mg daily were necessary to achieve a satisfactory reduction in blood pressure; these doses frequently induced gastrointestinal disturbances. Phenoxybenzamine, another alpha-receptor antagonist likewise never found wide favour in the treatment of hypertension, probably because of its pronounced cumulative effects (Nickerson, I962) . Hydralazine, a vasodilator drug with weak alphareceptor blocking activity achieved a temporary popularity (Freis, I962) , but the high doses necessary to achieve satisfactory control of the blood pressure with this drug alone often gave rise to unpleasant side effects and its use was quickly curtailed. Beta-receptor antagonists alone have also been advanced in the treatment of hypertension (Prichard and Gillam, I969; Zacharias and Cowen, I970) . However, the large doses (e.g. iooo mg propranolol daily or more) often necessary to achieve a satisfactory reduction in the blood pressure of severely hypertensive patients, the frequency of inadequate blood pressure control despite such large doses, and the possible long-term deleterious effects of such high doses on left ventricular function (Majid et al., 1970) (Sannerstedt et al., I97I) , in short-term oral studies (Gilmore, Weil, and 
